Strategic Advisory Partners LLC Acquires New Position in iShares Biotechnology ETF $IBB

Strategic Advisory Partners LLC bought a new position in shares of iShares Biotechnology ETF (NASDAQ:IBB) during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor bought 29,235 shares of the financial services provider’s stock, valued at approximately $4,934,000. iShares Biotechnology ETF accounts for about 4.1% of Strategic Advisory Partners LLC’s holdings, making the stock its 6th largest position. Strategic Advisory Partners LLC owned about 0.06% of iShares Biotechnology ETF at the end of the most recent quarter.

A number of other hedge funds also recently added to or reduced their stakes in the business. Citigroup Inc. grew its stake in shares of iShares Biotechnology ETF by 40.9% in the fourth quarter. Citigroup Inc. now owns 5,242,688 shares of the financial services provider’s stock worth $884,808,000 after acquiring an additional 1,521,992 shares in the last quarter. BNP Paribas Financial Markets boosted its holdings in iShares Biotechnology ETF by 313.2% in the third quarter. BNP Paribas Financial Markets now owns 1,915,395 shares of the financial services provider’s stock valued at $276,526,000 after purchasing an additional 1,451,820 shares during the period. Raymond James Financial Inc. grew its stake in iShares Biotechnology ETF by 286.2% during the 4th quarter. Raymond James Financial Inc. now owns 994,311 shares of the financial services provider’s stock worth $167,810,000 after purchasing an additional 736,881 shares in the last quarter. WestEnd Advisors LLC acquired a new position in iShares Biotechnology ETF during the 4th quarter worth $106,276,000. Finally, Truist Financial Corp increased its holdings in iShares Biotechnology ETF by 2,239.6% during the 4th quarter. Truist Financial Corp now owns 642,023 shares of the financial services provider’s stock worth $108,354,000 after purchasing an additional 614,582 shares during the period. 62.45% of the stock is currently owned by institutional investors and hedge funds.

iShares Biotechnology ETF Price Performance

IBB stock opened at $173.64 on Friday. The business’s 50-day moving average is $170.61 and its two-hundred day moving average is $170.66. iShares Biotechnology ETF has a 1 year low of $123.61 and a 1 year high of $179.64.

iShares Biotechnology ETF Cuts Dividend

The company also recently announced a quarterly dividend, which was paid on Thursday, June 18th. Investors of record on Monday, June 15th were paid a dividend of $0.0238 per share. This represents a $0.10 dividend on an annualized basis and a dividend yield of 0.1%. The ex-dividend date was Monday, June 15th.

iShares Biotechnology ETF Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.